Ginsenoside Rg1
(Synonyms: 人参皂苷 Rg1; Panaxoside A; Panaxoside Rg1) 目录号 : GN10544
人参皂苷Rg1是人参的主要活性成分之一，是一种具有多种生物活性的甾体糖苷。人参皂苷Rg1可降低大脑Aβ 水平并减少 NF-κB 核转移。
Cas No.:22427-39-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment [1]: |
|
|
Cell lines |
human dental pulp cells |
|
Preparation method |
hDPCs were incubated with different concentrations of ginsenoside Rg1 (0.1, 0.5, 2.5, 5, 10 and 20 μmol/L). The effects of ginsenoside Rg1 on the proliferative ability of hDPCs were evaluated by a fibroblast colony forming test, MTT assay and flow cytometry for cell cycle. DPCs were incubated with various concentrations of ginsenoside Rg1 for 1, 3, 5 and 7 days. |
|
Reaction Conditions |
0.1, 0.5, 2.5, 5, 10 and 20 μmol/L;1, 3, 5 and 7 days |
|
Applications |
Ginsenoside Rg 1 (5 μmol/L) significantly promoted the proliferation and differentiation of human dental pulp cells hDPC. Compared with the control group, ALP activity, DSPP and DMP 1 gene expression were increased in the induction group, ginsenoside Rg 1 group and the two combined groups. |
|
Animal experiment [2]: |
|
|
Animal models |
APP/PS1 mice |
|
Preparation method |
According to the concentration-response curves, the mice in the G-Rg1 and G-Rg2 groups were injected intraperitoneally once daily with G-Rg1 and G-Rg2 (30 mg/kg), respectively, dissolved in saline. The mice in the AD model group (APP/PS1 mice) and the normal control group (C57BL/6J nontransgenic littermates) were treated with isodose saline (0.9% w/v). All mice were treated for 1 month before brain metabolite profiling. |
|
Dosage form |
30 mg/kg；1 month |
|
Applications |
Ginsenoside Rg 1 and ginsenoside Rg 2 treatment (30 mg/kg; 1 month) effectively improved the cognitive function of APP/PS1 mice, and a gradual improvement in brain pathological abnormalities was observed, and the accumulation of Aβ deposits was effectively reduced. |
|
References: [1] Wang P, et al. Effect of ginsenoside Rg1 on proliferation and differentiation of human dental pulp cells in vitro. Aust Dent J. 2012 Jun;57(2):157-65. [2] Li N, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. J Ginseng Res. 2016 Jan;40(1):9-17. |
|
Ginsenoside Rg1, one of the main active components found in Panax ginseng, is a class of natural products known as steroid glycosides with a wide range of biological activities. Ginsenoside Rg1 has attracted significant attention due to its various pharmacological effects, including the promotion of hippocampal neurogenesis, improvement of neural plasticity, enhancement of learning and memory, anti-aging and anti-fatigue effects, as well as immunoregulatory and anti-tumor activities. Treatment with G-Rg1 has also been shown to significantly reduce the expression of TNF-α, IL-1β, and IL-6 in ischemia-reperfusion animal and cell models[1]. Ginsenoside Rg1 has been demonstrated to have significant neuroprotective effects, reduce brain levels of Aβ, and decrease NF-κB nuclear translocation, making it a potential therapeutic agent for neurodegenerative diseases such as Alzheimer's and Parkinson's diseases[4].
In vitro, ginsenoside Rg1 (5 μmol/L) significantly promoted the proliferation and differentiation of human dental pulp cells (hDPCs). Compared with the control group, the induced group, the ginsenoside Rg1 group, and the combination of both showed increased ALP activity and expressions of DSPP and DMP1 genes[1]. Another study indicated that Rg1 significantly reduced the levels of TNF-α and IL-6 in inflamed joints of AIA rats and LPS-stimulated RAW 264.7 cells, increased PPAR-γ protein expression, and inhibited the phosphorylation of IκBα and the nuclear translocation of NF-κB[2].
In vivo, intraperitoneal injection of Rg1 (5, 10, and 20 mg/kg) in AIA rats for 14 consecutive days showed therapeutic effects on arthritis, significantly alleviating joint swelling and damage[2]. Moreover, treatment with ginsenoside Rg1 and Rg2 (30 mg/kg; 1 month) effectively improved the cognitive function of APP/PS1 mice, observed gradual improvement in brain pathological abnormalities, and effectively reduced the accumulation of Aβ deposits[3].
References:
[1] Zhang L, et al. Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of PPAR-γ/NF-κB signal pathway. Oncotarget. 2017 Jul 24;8(33):55384-55393.
[2] Wang P, et al. Effect of ginsenoside Rg1 on proliferation and differentiation of human dental pulp cells in vitro. Aust Dent J. 2012 Jun;57(2):157-65.
[3] Li N, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. J Ginseng Res. 2016 Jan;40(1):9-17.
[4] Xie W , Zhou P , Sun Y ,et al. Protective Effects and Target Network Analysis of Ginsenoside Rg1 in Cerebral Ischemia and Reperfusion Injury: A Comprehensive Overview of Experimental Studies[J].Cells, 2018, 7(12).
人参皂苷Rg1是人参中发现的主要活性成分之一，人参皂苷Rg1是一类天然产物，是具有多种生物活性的甾体糖苷。人参皂苷Rg1因其多种药理作用而特别引人注目，可以促进海马神经发生，改善神经可塑性，增强学习记忆，发挥抗衰老和抗疲劳作用，调节免疫和抗肿瘤活性。人参皂苷Rg1已被证明具有显著的神经保护作用，还可以降低脑内Aβ水平，还减少NF-κB核转位，使其成为阿尔茨海默病和帕金森病等神经退行性疾病的潜在治疗剂[1]。人参皂苷Rg1治疗还显著降低了缺血-再灌注动物和细胞模型中TNF-α、IL-1β和IL-6的表达[4]。
在体外，人参皂苷Rg 1能显著降低脂多糖（LPS）刺激的AIA大鼠炎症关节和RAW 264. 7细胞中TNF-α和IL-6水平，增加PPAR-γ蛋白表达，抑制IκBα磷酸化和NF-κB核转位[1]。另一研究表明，人参皂苷Rg 1（5 μmol/L）明显促进人牙髓细胞hDPC的增殖和分化。与对照组相比，诱导组、人参皂苷Rg 1组及二者联合组ALP活性、DSPP和DMP 1基因表达均升高[2]。
在体内，给AIA大鼠腹腔注射Rg 1（5、10和20 mg/kg），连续14 d，观察其抗关节炎作用。结果表明，人参皂甙Rg 1对AIA大鼠具有治疗作用，能显著减轻关节肿胀和损伤[2]。此外，人参皂苷Rg 1和人参皂苷Rg 2治疗（30 mg/kg；1 month）有效地改善了APP/PS1小鼠的认知功能，观察到大脑病理异常逐渐改善，Aβ沉积物蓄积有效减少[3]。
| Cas No. | 22427-39-0 | SDF | |
| 别名 | 人参皂苷 Rg1; Panaxoside A; Panaxoside Rg1 | ||
| 化学名 | Ginsenoside Rg1 | ||
| Canonical SMILES | CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C)O)C)OC6C(C(C(C(O6)CO)O)O)O)C | ||
| 分子式 | C42H72O14 | 分子量 | 801.01 |
| 溶解度 | ≥ 32mg/mL in DMSO | 储存条件 | Store at 4°C Keep from the light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2484 mL | 6.2421 mL | 12.4842 mL |
| 5 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL |
| 10 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。